Mazdutide

Fat LossGLP-1/glucagon dual agonist (NMPA-approved; not FDA)Emerging

Dual GLP-1/glucagon agonist. NMPA-approved in China (2025) for weight management and T2D; not FDA-approved in the US.

For research use only.

Key Facts

Dual GLP-1/glucagon agonist. NMPA-approved in China (2025) for weight management and T2D; not FDA-approved in the US.

Dosage Range: China label uses 4–6 mg weekly class doses for weight management
Frequency: Once weekly
Cycle: —
Administration Route: Subcutaneous
Reconstitution Guide: —

Dual GLP-1R/GCGR agonism reduces energy intake and increases energy expenditure. Phase 3 Chinese programs supported local approval.

GLP-1 receptorGlucagon receptor

Approved in China; US investigational